← Back to Search

Cannabinoid

CBD for Anorexia Nervosa

Q: Which prior experiments have focused on the effects of Cannabidiol?

At present, 79 clinical trials for Cannabidiol are active with 16 of those in the third phase. Many investigations into this compound have taken place at Ribeirao Preto, Sao Paulo; however, 290 medical sites across the globe are conducting research on its efficacy.

Q: Is it possible to still join this medical experiment?

The clinical trial is still recruiting participants, and the latest update to the listing was on January 19th 2022 - with an initial posting of January 20th 2022.

Q: What is the eligibility criteria for participation in this clinical trial?

To be considered a viable candidate for this research, an individual should have anorexia nervosa and be within the 18-40 age range. The maximum number of participants in this trial is 40 people.

Q: Are individuals aged 18 and above eligible to participate in this experiment?

This research endeavor is open to applicants who are older than 18 years old and younger than 40.

Q: How many participants are slated to take part in this research endeavor?

Affirmative. As per the information posted on clinicaltrials.gov, this research is seeking participants at present time. It was originally announced on January 20th 2022 and has been updated as recently as January 19th of the same year. 40 patients are being sought from a single location for inclusion in this experiment.

Phase < 1

Recruiting

Led By Guido K Frank, MD

Research Sponsored by University of California, San Diego

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Have a duration of illness ≥ 6 months

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up weekly for the duration of the project (three weeks)

Awards & highlights

Study Summary

This trial is investigating whether cannabidiol (CBD), a component of marijuana, is an effective treatment for Anorexia Nervosa (AN).

Who is the study for?

This trial is for individuals with Anorexia Nervosa or related disorders, who have been ill for at least 6 months and are medically stable. Participants must meet specific diagnostic criteria without significant medication changes recently. Those with certain physical conditions, drug dependencies, or severe mental health issues cannot join.Check my eligibility

What is being tested?

The study tests the effects of Cannabidiol (CBD) on mealtime anxiety in people with Anorexia Nervosa. It aims to establish CBD's dosage, side effects, tolerability, and acceptability as a potential treatment by comparing it against a placebo.See study design

What are the potential side effects?

Potential side effects of CBD may include mild digestive upset, changes in appetite or mood, drowsiness or fatigue. However, since this is an exploratory study, part of its purpose is to document the range and frequency of any side effects experienced.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My illness has lasted for 6 months or more.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ after completion of week 3 of treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~after completion of week 3 of treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and after completion of week 3 of treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Blood tests for cannabinol (CBD) metabolites Week 1

Blood tests for cannabinol (CBD) metabolites Week 2

Hematologic Tests

+4 more

Side effects data

From 2022 Phase 2 & 3 trial • 90 Patients • NCT04387617

38%

Tiredness

24%

Drowsiness

24%

Poor sleep

22%

Constipation

18%

Poor Appetite

16%

Dizziness

Headache

Diarrhea

Nausea

Itching

100%

80%

60%

40%

20%

Study treatment Arm

CBD Oil Group

Control Group

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Cannabidiol (CBD)Experimental Treatment1 Intervention

Days 1 to 7: Patients will receive CBD 2.5 mg/kg in divided doses BID for 7 days. Days 8 to 14: Patients will receive an increase dose of 7.5 mg/kg of CBD in divided doses. Days 15 to 21: Patients will receive an increased dose of 12.5 mg/kg CBD, in divided doses. If patients experience dose limiting side-effects, they ill be maintained on the lowest tolerated dose.

Group II: PlaceboPlacebo Group1 Intervention

Days 1 to 7: Patients will receive placebo in divided doses BID for 7 days. Days 8 to 14: Patients will continue to receive placebo in divided doses. Days 15 to 21: Patients will receive continue to receive placebo in divided doses.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Cannabidiol

2021

Completed Phase 3

~1010

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of California, San DiegoLead Sponsor

1,121 Previous Clinical Trials

1,521,385 Total Patients Enrolled

15 Trials studying Anorexia Nervosa

1,574 Patients Enrolled for Anorexia Nervosa

Guido K Frank, MDPrincipal InvestigatorUniversity of California, San Diego

Media Library

Cannabidiol (Cannabinoid) Clinical Trial Eligibility Overview. Trial Name: NCT04878627 — Phase < 1

Anorexia Nervosa Research Study Groups: Cannabidiol (CBD), Placebo

Anorexia Nervosa Clinical Trial 2023: Cannabidiol Highlights & Side Effects. Trial Name: NCT04878627 — Phase < 1

Cannabidiol (Cannabinoid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04878627 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Which prior experiments have focused on the effects of Cannabidiol?

"At present, 79 clinical trials for Cannabidiol are active with 16 of those in the third phase. Many investigations into this compound have taken place at Ribeirao Preto, Sao Paulo; however, 290 medical sites across the globe are conducting research on its efficacy."

Answered by AI

Is it possible to still join this medical experiment?

"The clinical trial is still recruiting participants, and the latest update to the listing was on January 19th 2022 - with an initial posting of January 20th 2022."

Answered by AI

What is the eligibility criteria for participation in this clinical trial?

"To be considered a viable candidate for this research, an individual should have anorexia nervosa and be within the 18-40 age range. The maximum number of participants in this trial is 40 people."

Answered by AI

Are individuals aged 18 and above eligible to participate in this experiment?

"This research endeavor is open to applicants who are older than 18 years old and younger than 40."

Answered by AI

How many participants are slated to take part in this research endeavor?

"Affirmative. As per the information posted on clinicaltrials.gov, this research is seeking participants at present time. It was originally announced on January 20th 2022 and has been updated as recently as January 19th of the same year. 40 patients are being sought from a single location for inclusion in this experiment."

Answered by AI